IP Library › Granted Patent US 10,053,489
Granted Patent B2
US 10,053,489 · App. 14/896,380 · Granted Aug 21, 2018

Method for purifying antibody

Inventors: Soo Kwang Kim (Daejeon, KR); Yong Ho Ahn (Daejeon, KR); Young Min Kim (Gyeonggi-do, KR); Dae Hae Song (Daejeon, KR)
Assignee: Prestige Biopharma PTE, LTD
C07K1/18C07K16/065C07K16/22C07K16/241
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,053,489
App. No.
14/896,380
Granted
Aug 21, 2018
Kind
B2
Abstract

The present invention relates to a method of purifying an antibody with high purity and high quality by removing impurities by sequential use of a cation-exchange column, a culture supernatant multilayer filter and an anion-exchange column without using a protein-A column that is an affinity chromatography column which is generally used for antibody purification.

Claims (20)

1. A method for purifying an antibody, the method comprising:

(a) loading a sample, which comprises the antibody and at least one host cell protein (HCP) and has a pH of 5.5-7.0 and a conductivity of 5-7 mS/cm, into an equilibrated cation-exchange column, washing the cation-exchange column, and then eluting the antibody bound to the column with elution buffer;

(b) passing the eluate of step (a) through a multilayer filter, and collecting the filtrate; and

(c) passing the filtrate of step (b) through an anion-exchange column, and collecting the flow-through.

2. The method according to claim 1 , wherein the antibody has an isoelectric point of 7-10.

3. The method according to claim 1 , wherein the antibody is Bevacizumab or Adalimumab.

4. The method according to claim 1 , wherein the content of host cell protein (HCP) in the antibody eluate of step (a) is 95-99.5% lower than that in the loaded sample.

5. The method according to claim 1 , wherein the cation exchange column has a functional group selected from the group consisting of carboxymethyl (CM), sulfoethyl (SE), sulfopropyl (SP), phosphate (P) and sulfonate (S).

6. The method according to claim 5 , wherein the cation exchange column having sulfonate as a functional group comprises a cross-linked polymethacrylate resin.

7. The method according to claim 6 , wherein step (a) comprises:

(i) loading the sample comprising the antibody onto the cation exchange column equilibrated with an equilibration buffer comprising 10-50 mM phosphate (pH 5.5-7.0);

(ii) washing the cation exchange column with a buffer comprising 20-40 mM sodium chloride and 10-50 mM phosphate (pH 6.0-7.0); and

(iii) eluting the antibody with an elution buffer comprising 50-200 mM sodium chloride and 10-50 mM phosphate (pH 6.0-7.0).

8. The method according to claim 1 , wherein the multilayer filter has a product water conductivity of 8.66-10.5 μS/cm or 19.34-53.2 μS/cm post autoclave and pure water flush of 10 liters per ft 2 (100 L/m 2 ) of surface area of the multilayer filter.

9. The method according to claim 1 , wherein the antibody eluate of step (b) is subjected to viral inactivation before it is passed through the multilayer filter.

10. The method according to claim 1 , wherein the antibody eluate of step (b) is adjusted to a pH of 5.5-7.0 before it is passed through the multilayer filter.

11. The method according to claim 1 , wherein the content of host cell protein (HCP) in the filtrate of step (b) is 1,200-2,500 times lower than that in the antibody eluate of step (a).

12. The method according to claim 1 , wherein the anion exchange column in step (c) has a functional group of a quartenary amine and further comprises a cross-linked agarose base matrix.

13. The method according to claim 1 , wherein the content of host cell protein (HCP) in the protein purified by the method is 0.001-10 ppm.

14. The method according to claim 1 , wherein the method comprises no additional column chromatography step.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 7, 2016
From: KIM, SOO KWANG; KIM, YOUNG MIN; AHN, YONG HO; SONG, DAE HAE
To: PRESTIGE BIOPHARMA PTE., LTD
Reel/Frame 037680/0635 →
Priority Claims (1)
KR 10-2013-0064803 · Jun 5, 2013 · national
Continuity (1)
Related Publication 20160122384A1 · May 5, 2016
Cited By (1)
US 12,594,337